Clinical response of patients with galactorrhea to pergolide, a potent, long-acting dopaminergic ergot derivative

J. T. Callaghan, R. E. Cleary, R. Crabtree, L. Lemberger

Research output: Contribution to journalArticle

15 Scopus citations


Pergolide is an ergot derivative with dopaminergic activity and, like bromocriptine, can suppress prolactin release from the pituitary gland. In a single blind study pergolide was administered for 90 days to three females with idiopathic hyperprolactinemia manifested by galactorrhea and amenorrhea. Response to therapy was followed clinically and by determination of plasma prolactin concentrations. Pergolide lowered plasma prolactin concentrations and suppressed galactorrhea in all patients. Menstruation recurred in both patients with intact GU systems. Side effects were minor and tolerance developed to all but nasal stuffiness. Pergolide appears to be efficacious therapy for patients with amenorrhea/galactorrhea secondary to hyperprolactinemia.

Original languageEnglish (US)
Pages (from-to)95-102
Number of pages8
JournalLife Sciences
Issue number1
StatePublished - Jan 5 1981


ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this